Procter & Gamble Health Ltd
₹5216.90
(1.59%)
Thu, 30 Apr 2026, 11:45 pm
Health Technology
Pharmaceuticals: Major
24.5KProcter & Gamble Health EV/EBITDA Ratio
| Particulars | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 13.32 | 11.14 | 5.64 | 10.96 | 8.09 | 14.80 | 18.81 | 15.50 | 13.77 | 16.65 | 30.57 | 24.12 | 20.91 | 22.78 | 6.10 | 39.86 | 52.52 | 36.10 | 37.97 | 36.41 |
| Price to book ratio | 3.81 | 2.94 | 1.91 | 1.78 | 1.13 | 2.05 | 3.43 | 2.41 | 2.23 | 1.78 | 2.38 | 2.19 | 2.49 | 2.92 | 3.32 | 7.45 | 13.20 | 11.28 | 11.61 | 15.90 |
| Price to sales ratio | 2.52 | 2.23 | 2.28 | 2.39 | 1.31 | 2.05 | 2.34 | 1.77 | 1.58 | 1.17 | 1.52 | 1.38 | 1.67 | 3.06 | 6.04 | 7.47 | 9.21 | 6.25 | 7.09 | 6.85 |
| Price to cash flow ratio | 12.05 | 11.37 | 9.28 | 12.49 | 15.29 | 14.86 | 13.34 | 0 | 15.51 | 46.51 | 54.70 | 12.97 | 13.48 | 29.10 | 0 | 22.81 | 35.13 | 38.74 | 34.83 | 48.54 |
| Enterprise value | 9B | 7.93B | 6.46B | 6.37B | 3.26B | 6.43B | 10.47B | 8.75B | 8.62B | 7.2B | 11.31B | 10.63B | 13.49B | 17.91B | 38.76B | 61.12B | 88.24B | 66.29B | 82.85B | 83.55B |
| Enterprise value to EBITDA ratio | 8.61 | 7.39 | 8.26 | 9.64 | 6.72 | 10.68 | 14.18 | 21.51 | 8.52 | 9.79 | 19.89 | 12.45 | 10.72 | 18.67 | 25.98 | 28.28 | 34.89 | 24.47 | 25.18 | 19.32 |
| Debt to equity ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 | 0.02 | 0.01 |
| Return on equity % | 31.95 | 28.84 | 38.59 | 16.87 | 14.41 | 14.26 | 15.53 | 16.84 | 17.54 | 11.10 | 8.02 | 9.35 | 12.61 | 8.74 | 8.95 | 0 | 21.96 | 29.17 | 33.57 | 48.55 |
Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio
The Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Procter & Gamble Health Ltd's valuation, profitability, and overall financial performance. Tracking the Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Procter & Gamble Health Ltd (NSE: PGHL, BSE: 500126) is currently trading at ₹5216.90, with a market capitalization of ₹85.09B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio Current Value
The current Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio stands at 19.32.
The Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 19.32
- 2023: 25.18
- 2022: 24.47
- 2021: 34.89
- 2020: 28.28
The decline in Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.
What Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Procter & Gamble Health Ltd.
Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Procter & Gamble Health Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800